Duration and effect of new formulation of botulinum toxin type a, daxibotulinumtoxina on glabellar lines: Systematic review
DOI:
https://doi.org/10.56294/piii2024356Keywords:
Botox, Botulinumtoxin, botulinumtoxins, typeA, DAXI, DaxibotulinumtoxinAAbstract
Background: "DaxibotulinumtoxinA (DAXI), an injectable formulation of botulinumtoxintype A, iscurrently underclinical development for treating glabellarlines, as well as various neurological and musculoskeletal conditions. This review under scores the significance of the know ledge that medical profesional spossess in enhancing the quality of specific anatomical relationships related to the reduction of glabellar lines and determining the irmosten during effects. Material and methods: The chosen methodology for this study is a systematic review and information collection. A manual search was conducted on online data bases, particularly PUBMED, using key Words such as "treatmentofglabellarlines" or "botulinumtoxin new formulation," with specific filters applied. Approximately 14 files were down loaded and organize during the Zotero program for propercitations and references. There search is supported by published and updated literatura that demonstrates the efficacy and duration of glabellar lines with the new formulation of Botulinum toxin, DaxibotulinumtoxinA. Results: Seven articles of the clinical trial or controlled randomized trial type were utilized. These articles, searched and filtered from various databases, collectively indicate that injectable DaxibotulinumtoxinA is a highly effective new formulation for treating glabellarlines. . Conclusion: Following the conducted search, it is evidente that DaxibotulinumtoxinA is avaluable option for a esthetically treating glabellar lines. How ever, it is a knowledged that further research is necessary to valídate its effectiveness compared to other convention altreatments and to assessits specific clinical applicability. Additionally, an evaluation of the elimitations and adverse effects associated with this new formulation is crucial
References
Brin MF. Entering the 4th decade of Botox (onabotulinumtoxinA): A narrative review of its development and impact on patients and medicine. Medicine (Baltimore). 1 de julio de 2023;102(S1):e32370.
Scott AB, Honeychurch D, Brin MF. Early development history of Botox (onabotulinumtoxinA). Medicine (Baltimore). 1 de julio de 2023;102(S1):e32371.
Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. Toxins. 5 de febrero de 2021;13(2):120.
Hanna E, Pon K. Updates on Botulinum Neurotoxins in Dermatology. Am J Clin Dermatol. abril de 2020;21(2):157-62.
Dong M, Masuyer G, Stenmark P. Botulinum and Tetanus Neurotoxins. Annu Rev Biochem. 20 de junio de 2019;88(1):811-37.
Ong AA, Sherris DA. Neurotoxins. Facial Plast Surg. junio de 2019;35(03):230-8.
Eleopra R, Rinaldo S, Montecucco C, Rossetto O, Devigili G. Clinical duration of action of different botulinum toxin types in humans. Toxicon. mayo de 2020;179:84-91.
Dressler D. Therapeutically relevant features of botulinum toxin drugs. Toxicon. febrero de 2020;175:64-8.
Carr WW, Jain N, Sublett JW. Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications. Adv Ther. octubre de 2021;38(10):504664.
Patil A, Kassir M, Wollina U, Goldust M. Neue Botulinumtoxine in der ästhetischen Dermatologie: Ein umfassender Überblick. Hautarzt. mayo de 2021;72(5):393-402.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Valeria Estefanía Pérez Zambrano, Marcelo Adrián Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
